Pertile P - Search Results

1

Mechanism underlying superantigen-induced clonal deletion of mature T lymphocytes.

Biasi G, Panozzo M, Pertile P, Mezzalira S, Facchinetti A. Biasi G, et al. Among authors: pertile p. Int Immunol. 1994 Jul;6(7):983-9. doi: 10.1093/intimm/6.7.983. Int Immunol. 1994. PMID: 7947466

2

In vivo and in vitro death of mature T cells induced by separate signals to CD4 and alpha beta TCR.

Facchinetti A, Panozzo M, Pertile P, Tessarollo L, Biasi G. Facchinetti A, et al. Among authors: pertile p. Immunobiology. 1992 Aug;185(2-4):380-9. doi: 10.1016/s0171-2985(11)80654-6. Immunobiology. 1992. PMID: 1452211 Review.

3

Apoptosis of mature T lymphocytes.

Biasi G, Facchinetti A, Panozzo M, Pertile P. Biasi G, et al. Among authors: pertile p. Ann N Y Acad Sci. 1992 Nov 21;663:481-2. doi: 10.1111/j.1749-6632.1992.tb38709.x. Ann N Y Acad Sci. 1992. PMID: 1482094 No abstract available.

4

Intracrine sex steroid synthesis and signaling in human epidermal keratinocytes and dermal fibroblasts.

Pomari E, Dalla Valle L, Pertile P, Colombo L, Thornton MJ. Pomari E, et al. Among authors: pertile p. FASEB J. 2015 Feb;29(2):508-24. doi: 10.1096/fj.14-251363. Epub 2014 Nov 12. FASEB J. 2015. PMID: 25392269

5

Two-part payments for the reimbursement of investments in health technologies.

Levaggi R, Moretto M, Pertile P. Levaggi R, et al. Among authors: pertile p. Health Policy. 2014 Apr;115(2-3):230-6. doi: 10.1016/j.healthpol.2013.10.006. Epub 2013 Oct 30. Health Policy. 2014. PMID: 24268054

6

Static and dynamic efficiency of irreversible health care investments under alternative payment rules.

Levaggi R, Moretto M, Pertile P. Levaggi R, et al. Among authors: pertile p. J Health Econ. 2012 Jan;31(1):169-79. doi: 10.1016/j.jhealeco.2011.09.005. Epub 2011 Oct 1. J Health Econ. 2012. PMID: 22019114 Free article.

7

Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition.

Levaggi R, Pertile P. Levaggi R, et al. Among authors: pertile p. Appl Health Econ Health Policy. 2020 Jun;18(3):357-362. doi: 10.1007/s40258-019-00541-z. Appl Health Econ Health Policy. 2020. PMID: 31788763

8

Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition".

Levaggi R, Pertile P. Levaggi R, et al. Among authors: pertile p. Appl Health Econ Health Policy. 2020 Jun;18(3):455-456. doi: 10.1007/s40258-020-00557-w. Appl Health Econ Health Policy. 2020. PMID: 32016831 No abstract available.

9

Which valued-based price when patients are heterogeneous?

Levaggi R, Pertile P. Levaggi R, et al. Among authors: pertile p. Health Econ. 2020 Aug;29(8):923-935. doi: 10.1002/hec.4033. Epub 2020 Jun 14. Health Econ. 2020. PMID: 32537816

10

A reply to "Who would benefit from average value-based pricing?".

Levaggi R, Pertile P. Levaggi R, et al. Among authors: pertile p. Health Econ. 2021 Sep;30(9):2284-2286. doi: 10.1002/hec.4392. Epub 2021 Jul 9. Health Econ. 2021. PMID: 34245084 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters